Document Detail


Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
MedLine Citation:
PMID:  17875944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Implantable cardioverter defibrillators (ICDs) are increasingly used for the prevention of sudden cardiac death in patients with life-threatening ventricular arrhythmias (VAs); however, there is a potential for severe and debilitating anxiety caused by symptoms associated with ICD therapy and anticipation of shocks. Anxiety is a psycho-logic stressor, including physiologic components that may lead to adrenergic excitation triggering new arrhythmias and ICD therapies. This often requires concomitant antiarrhythmic medication to reduce the frequency of shocks and symptomatic arrhythmias treated by anti-tachycardia pacing. Although published studies have documented the efficacy of currently available antiarrhythmics, they have limitations in patients with heart failure, may affect the defibrillation threshold, and/or have been associated with major side-effects. In conclusion, for the patient with an ICD experiencing symptomatic ventricular tachycardia (VTs) episodes or ICD shocks, there is a need for pharmacologic therapy to reduce the incidence of such events without affecting the performance of the ICD or causing major side-effects.
Authors:
Steven Singh; Matthew M Murawski
Related Documents :
6289274 - Myocardial damage following transthoracic direct current countershock in newborn piglets.
25485424 - Structured dictionaries for ischemia estimation in cardiac bold mri at rest.
25208724 - The ecg of high-level junior soccer players: comparing the esc vs. the seattle criteria.
7594054 - Atrial defibrillation using temporary epicardial defibrillation stainless steel wire el...
21917414 - Usefulness of adjunctive pulse infusion thrombolysis after failed aspiration for massiv...
1457854 - Quantitation of right ventricular shape changes after left ventricular assist device im...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  12     ISSN:  1074-2484     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-09-18     Completed Date:  2007-10-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  175-80     Citation Subset:  IM    
Affiliation:
Veterans Affairs Medical Center, Washington, DC 20422, USA. steve.singh@med.va.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Arrhythmia Agents / adverse effects,  therapeutic use*
Anxiety
Combined Modality Therapy
Death, Sudden, Cardiac / prevention & control
Defibrillators, Implantable* / adverse effects
Electric Countershock
Humans
Quality of Life
Tachycardia, Ventricular / therapy*
Ventricular Fibrillation / therapy*
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epigenetic control of the immune escape mechanisms in malignant carcinomas.
Next Document:  Supernormal conduction in the anomalous bundles of the Wolff-Parkinson-White syndrome: an overlooked...